Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

By S. Salpeter, E. Greyber, G. Pasternak, Edwin E Salpeter Posthumous. Cochrane Database of Systematic Reviews, 2003

668 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8c895c07d0ba5181dc6a21b7528ef8ff169b7f2d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008, unknown): “Renal dysfunction is considered a contraindication to metformin use because it may increase the risk of lactic acidosis, an extremely rare (less than one case per 100,000 treated patients) but potentially fatal complication [51].”
Clinical Pharmacokinetics of Metformin (2011, background): “Furthermore, no case of lactic acidosis was recorded in clinical trials on metformin.([79]) These trials included studies over more than 70 000 patientyears of metformin treatment but patient selection to exclude patients with risk factors for lactic acidosis and good patient care may well have cont”
Grading quality of evidence and strength of recommendations in clinical practice guidelines (2009, background): “Nevertheless, very large observational studies have failed to demonstrate an association (57).”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “In a review [66] of 347 randomized trials and prospective cohort studies, there were no cases of lactic acidosis.”
Etiology and therapeutic approach to elevated lactate levels. (2013, background): “Recently, a major Cochrane meta-analysis concluded that there was no increased risk of elevated lactate levels for metformin compared with nonmetformin treatment; however, this may reflect use in selected study populations and not necessarily those with overdoses or use in renal insufficiency, for e”
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014, background): “4 mg/dL [124 mmol/L] in women)may be overly restrictive (33).”
Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus (2007, background): “We found a systematic review that reported similar rates of lactic acidosis between metformin and other oral diabetes agents (35).”
Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines (2011, background): “The risk of lactic acidosis with metformin appears to be no greater than that with sulphonylurea [146, 147].”
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. (2012, background): “73 m(2) range, lactic acidosis is still exceedingly rare even in the presence of comorbid conditions like congestive heart failure, chronic obstructive pulmonary disease, and liver disease.(53,54) Given its marked clinical benefit, restriction of metformin use based on the creatinine cutoffs provide”
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015, background): “4 mg/dl] in women) may be overly restrictive [33].”
Diabetic Kidney Disease: A Report From an ADA Consensus Conference (2014, unknown): “Despite these concerns and published case reports (85), current data indicate the overall risk of metformin-associated lactic acidosis is low (86,87).”
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “However, the risk for lactic acidosis in patients on metformin is extremely low (87), and the FDA guidelines prevent many individuals from benefiting from metformin.”
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009, background): “Renal dysfunction is considered a contraindication to metformin use because it may increase the risk of lactic acidosis, an extremely rare (less than 1 case per 100,000 treated patients) but potentially fatal complication (51).”
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. (2014, background): “It is now recognized that the risk for lactic acidosis in patients on metformin is extremely low, and the KDIGO guidelines reflects this new evidence.(60)”